Non-selective inhibitor of dopamine and noradrenalin transporters (Ki values are 1.4, 2.8 and 45 μM for NET, DAT and SERT transporters respectively). Also inhibits neuronal nicotinic acetylcholine receptors. Displays antidepressant activity and augments nicotine self-administration at low doses in vivo.
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 276.2. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.62 mL||18.1 mL||36.21 mL|
|5 mM||0.72 mL||3.62 mL||7.24 mL|
|10 mM||0.36 mL||1.81 mL||3.62 mL|
|50 mM||0.07 mL||0.36 mL||0.72 mL|
References are publications that support the biological activity of the product.
Slemmer et al (2000) Bupropion is a nicotinic antagonist. J.Pharmacol.Exp.Ther. 295 321 PMID: 10991997
Torres et al (2003) Plasma membrane monoamine transporters: structure regulation and function. Nat.Rev.Neurosci. 4 13 PMID: 12511858
Dwoskin et al (2006) Review of the pharmacology and clinical profile of bupropion, antidepressant and tobacco use cessation agent. CNS Drug Rev. 12 178 PMID: 17227286
If you know of a relevant reference for Bupropion hydrochloride, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Bupropion hydrochloride, Bupropion hydrochloride supplier, Non-Selective, inhibitors, inhibits, dopamine, noradrenaline, transporters, NET, Adrenergic, Monoamine, Neurotransmitter, DAT, Dopamine, reuptake, Transporters, 2831, Tocris Bioscience
3 Citations for Bupropion hydrochloride
Citations are publications that use Tocris products. Selected citations for Bupropion hydrochloride include:
Czysz et al (2015) Lateral diffusion of Gαs in the plasma membrane is decreased after chronic but not acute antidepressant treatment: role of lipid raft and non-raft membrane microdomains. Cardiovasc Res 40 766 PMID: 25249058
Nunes et al (2013) Effort-related motivational effects of the VMAT-2 inhibitor tetrabenazine: implications for animal models of the motivational symptoms of depression. J Neurosci 33 19120 PMID: 24305809
Li et al (2009) Activation of glycogen synthase kinase-3 β is required for hyperdopamine and D2 receptor-mediated inhibition of synaptic NMDA receptor function in the rat prefrontal cortex. Neuropsychopharmacology 29 15551 PMID: 20007479
Do you know of a great paper that uses Bupropion hydrochloride from Tocris? Please let us know.
Reviews for Bupropion hydrochloride
There are currently no reviews for this product. Be the first to review Bupropion hydrochloride and earn rewards!
Have you used Bupropion hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.